Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases

Xenobiotica

Volumn 38, Issue 2, 2008, Pages 185-222

  Bi, H C ^a   Zuo, Z ^b   Chen, X ^a   Xu, C S ^a   Wen, Y Y ^a   Sun, H Y ^a   Zhao, L Z ^a   Pan, Y ^a   Deng, Y ^a   Liu, P Q ^a   Gu, L Q ^a   Huang, Z Y ^a   Zhou, S F ^c   Huang, M ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c RMIT UNIVERSITY   (Australia)

Author keywords

Absorption; Enterohepatic circulation; Excretion; First pass effect; Glucuronide; LC MS MS; Pharmacokinetics; Tanshionone IIA

Indexed keywords

AGLYCONE; CORN OIL; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 3A; GLUCURONIDE; KETOCONAZOLE; QUINIDINE; SALVIA MILTIORRHIZA EXTRACT; TANSHINONE; TANSHINONE 2A; TICLOPIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE DUCT; BILIARY EXCRETION; CANNULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TRANSPORT; FECES; HYDROLYSIS; ISCHEMIC HEART DISEASE; LIVER MICROSOME; MALE; NONHUMAN; RAT; SALVIA MILTIORRHIZA; SINGLE DRUG DOSE; URINARY EXCRETION;

ANIMALS; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MODELS, ANIMAL; MYOCARDIAL ISCHEMIA; PHENANTHRENES; PLANT ROOTS; RATS; RATS, SPRAGUE-DAWLEY; SALVIA MILTIORRHIZA; TIME FACTORS;

RATTUS; SALVIA MILTIORRHIZA;

EID: 38149068306     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701767675     Document Type: Article

References (71)

1. Adams JD, Wang R, Yang J, Lien EJ. 2006. Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chinese Medicine 1:1-15.
2. An LK, Bu XZ, Wu HQ, Guo XD, Ma L, Gu LQ. 2002. Reaction of tanshinones with biogenic amine metabolites in vitro. Tetrahedrom 58:10315-10321.
3. Bi HC, Law FC, Zhong GP, Xu CS, Pan Y, Ding L, Chen X, Zhao LZ, Xu Q, Huang M. 2007. Study of tanshinone IIA tissue distribution in rat by liquid chromatography-tandem mass spectrometry method. Biomedical Chromatography 21:473-479.
4. Bu XZ, Huang ZS, Zhang M, Ma L, Xiao GW, Gu LQ. 2001. Synthesis of new 1,1-dimethyl-1,2,3,4,-tetrahydrophenanthrene derivatives. Tetrahedrom Letters 42:5753-5740.
5. Chang HM, Chen KP, Choang TF, Chow HF, Chui Y, Hon PM, Lau Tan FW, Yang Y, Zhong ZP, Lee M, et al. 1990. Structure elucidation and total synthesis of new tanshinones isolated from Salvia miltiorriza Bunge (Danshen). Journal of Organic Chemistry 55:3537-3543.
6. Chang PN, Mao JC, Huang SH, Ning L, Wang ZJ, On T, Duan W, Zhu YZ. 2006. Analysis of cardioprotective effects using purified Salvia miltiorrhiza extract on isolated rat hearts. Journal of Pharmacology Science 101:245-249.
7. Chen TH, Hsu YT, Chen CH, Kao SH, Lee HM. 2007a. Tanshinone IIA from Salvia miltiorrhiza induces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in RAW 264. 7 cells. Mitochondrion 7:101-105.
8. Chen X, Yin OQ, Zuo Z, Chow MS. 2005. Pharmacokinetics and modeling of quercetin and metabolites. Pharmacology Research 22:892-901.
9. Chen X, Zhou ZW, Xue CC, Li XX, Zhou SF. 2007b. Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier. Xenobiotica 37:635-678.
10. Cheng TO. 2006a. Danshen: A popular Chinese cardiac herbal drug. Journal of the American College of Cardiology 47:1498.
11. Cheng TO. 2006b. Danshen: What every cardiologist should know about this Chinese herbal drug. International Journal of Cardiology 110:411-412.
12. Choudhury R, Chowrimootoo G, Srai K, Debnam E, Rice-Evans CA. 1999. Interactions of the flavonoid naringenin in the gastrointestinal tract and the influence of glycosylation. Biochemical and Biophysical Research Communication 265:410-415.
13. Cummins CL, Salphati L, Reid MJ, Benet LZ. 2003. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model. Journal of Pharmacology and Experimental Therapy 305:306-314.
14. Danheiser RL, Casebier DS, Loebach JL. 1992. Total synthesis of dan shen diterpenoid quinones. Tetrahedron Letters 33:1149-1152.
15. Don MJ, Shen CC, Syu WJ, Ding YH, Sun CM. 2006. Cytotoxic and aromatic constituents from Salvia miltiorrhiza. Phytochemistry 67:497-503.
16. Eeckhoudt SL, Evrard PA, Verbeeck RK. 1997. Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. Drug Metabolism and Disposition 25:428-430.
17. Gu M, Zhang G, Su Z, Ouyang F. 2004. Identification of major active constituents in the fingerprint of Salvia miltiorrhiza Bunge developed by high-speed counter-current chromatography. Journal of Chromatography A 1041:239-243.
18. Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. 2006. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Medica 72:1311-1317.
19. Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. 2007. Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Current Drug Metabolism 8:137-149.
20. Hasselstrom J, Sawe J. 1993. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clinical Pharmacokinetics 24:344-354.
21. He F, Bi HC, Xie ZY, Zuo Z, Li JK, Li X, Zhao LZ, Chen X, Huang M. 2007. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: Application to high-throughput inhibition screening of terpenoids. Rapid Communications in Mass Spectrometry 21:635-643.
22. Huang KJ, Wang H, Xie WZ, Zhang HS. 2007. Investigation of the effect of tanshinone IIA on nitric oxide production in human vascular endothelial cells by fluorescence imaging. Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy.
23. Ichikawa T, Ishida S, Sakiya Y, Sawada Y, Hanano M. 1986. Biliary excretion and enterohepatic cycling of glycyrrhizin in rats. Journal of Pharmacology Science 75:672-675.
24. Imanshahidi M, Hosseinzadeh H. 2006. The pharmacological effects of Salvia species on the central nervous system. Phytotherapy Research 20:427-437.
25. Jang SI, Jeong SI, Kim KJ, Kim HJ, Yu HH, Park R, Kim HM, You YO. 2003. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Planta Medica 69:1057-1059.
26. Jang SI, Kim HJ, Kim YJ, Jeong SI, You YO. 2006. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264. 7 cells: Possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. European Journal of Pharmacology 542:1-7.
27. Ji XY, Tan BK, Zhu YZ. 2000. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacologica Sinica 21:1089-1094.
28. Jiang B, Yin CH. 2002. Study on the bioavailability of silymarin-phosphatidylcholine complex in rabbits. Chinese Journal of Pharmaceuticals 33:598-600.
29. Langguth P, Lee KM, Spahn-Langguth H, Amidon GL. 1994. Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharmaceutics and Drug Disposition 15:719-46.
30. Lee J, Li JH, Oya S, Snyder JK. 1992. Asymmetric synthesis of tanshindiol A. Journal of Organic Chemistry 57:5301-5312.
31. Lee SY, Choi DY, Woo ER. 2005. Inhibition of osteoclast differentiation by tanshinones from the root of Salvia miltiorrhiza bunge. Archives of Pharmacology Research 28:909-913.
32. Li J, Zhou S, Huynh H, Chan E. 2005. Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharmacology Research 22:397-404.
33. Li P, Wang GJ, Li J, Hao HP, Zheng CN. 2006a. Characterization of metabolites of tanshinone IIA in rats by liquid chromatography/tandem mass spectrometry. Journal of Mass Spectrometry 41:670-684.
34. Li P, Wang GJ, Li J, Hao HP, Zheng CN. 2006b. Identification of tanshinone IIA metabolites in rat liver microsomes by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 1104:366-369.
35. Li P, Wang GJ, Li J, Hao HP, Zheng CN. 2006c. Simultaneous determination of tanshinone IIA and its three hydroxylated metabolites by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 20:815-822.
36. Lipka E, Lee ID, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL. 1995. Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. Journal of Pharmacokinetics and Biopharmaceutics 23:267-86.
37. Liu AH, Li L, Xu M, Lin YH, Guo HZ, Guo DA. 2006. Simultaneous quantification of six major phenolic acids in the roots of Salvia miltiorrhiza and four related traditional Chinese medicinal preparations by HPLC-DAD method. Journal of Pharmacology and Biomedical Analysis 41:48-56.
38. Lu T, Song J, Xie L, Wang GJ, Liu XD. 2005. Simultaneous determination of baicalin and wogonoside by HPLC in rat plasma administered with Huangqin Decoction and its pharmacokinetic study. Chinese Traditional Herbal Drugs 36:870-873.
39. Ma L, Zhang X, Guo H, Gan Y. 2006. Determination of four water-soluble compounds in Salvia miltiorrhiza Bunge by high-performance liquid chromatography with a coulometric electrode array system. Journal of Chromatography B: Analytical, Technological, and Biomedical Life Sciences 833:260-263.
40. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. 2002. Metabolism and disposition of reserratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. Journal of Pharmacology and Experimental Therapy 302:369-373.
41. Mehvar R, Vuppugalla R. 2006. Hepatic disposition of the cytochrome P450 2E1 marker chlorzoxazone and its hydroxylated metabolite in isolated perfused rat livers. Journal of Pharmacology Science 95:1414-1424.
42. Mirfazaelian A, Mahmoudian M. 2006. A simple pharmacokinetics subroutine for modeling double peak phenomenon. Biopharmaceutical Drug Disposition 27:119-124.
43. Ou WP, Mi SQ, Huang TL, Ye SM. 2000. Determination of psoralen by HPLC and its application in pharmacokinetic study. Zhongyao Xinyao Yu Linchuang Yaoli 11:107-109.
44. Qiao JP, Hou PL, Li YW, Abliz Z. 2003. Determination of tanshinone IIA in rat plasma and the pharmacokinetics by RP-HPLC method. Yao Xue Xue Bao 38:368-370.
45. Shanghai Cooperative Group for the Study of Tanshinone IIA. 1984. Therapeutic effect of sodium tanshinone IIA sulfonate in patients with coronary heart disease. A double blind study. Shanghai Cooperative Group for the Study of Tanshinone IIA. Journal of Traditional Chinese Medicine 4:20-24.
46. Shinkuma D, Hamaguchi T, Yamanaka Y, Mizuno N, Yata N. 1985. Influence of bile on the gastrointestinal absorption of phenytoin in rats. Chemistry and Pharmacology Bulletin (Tokyo) 33:5023-5027.
47. Sze FK, Yeung FF, Wong E, Lau J. 2005. Does Danshen improve disability after acute ischaemic stroke?. Acta Neurologica Scandinavica 111:118-125.
48. Takahashi K, Ouyang X, Komatsu K, Nakamura N, Hattori M, Baba A, Azuma J. 2002. Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells. Biochemistry and Pharmacology 64:745-749.
49. Tang F, Wu X, Wang T, Wang P, Li R, Zhang H, Gao J, Chen S, Bao L, Huang H, Liu P. 2007. Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascular Pharmacology.
50. Tao YY, Liu CH. 2004. Progress of research on mechanism of salvia miltiorrhiza and its chemical ingredients against liver fibrosis. Zhong Xi Yi Jie He Xue Bao 2:145-148.
51. The Pharmacopoeia Commission of PRC. 2005. Pharmacopoeia of the People's Republic of China version 2005 Vol. 1. Beijing: Beijing Chemical Industry Press.
52. Traber MG, Kayden HJ, Green JB, Green MH. 1986. Absorption of water-miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats. American Journal of Clinical Nutrition 44:914-923.
53. Wang J, Wang X, Jiang S, Yuan S, Lin P, Zhang J, Lu Y, Wang Q, Xiong Z, Wu Y, et al. 2007a. Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. Journal of Neurooncology 82:11-21.
54. Wang L, Xiong ZY, Wang G. 2004. Systematic assessment on randomized controlled trials for treatment of stable angina pectoris by compound salvia pellet. Zhongguo Zhong Xi Yi Jie He Za Zhi 24:500-504.
55. Wang X, Morris-Natschke SL, Lee KH. 2007b. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Medical Research Review 27:133-148.
56. Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J, Wang W. 2005. Potential anticancer activity of tanshinone IIA against human breast cancer. International Journal of Cancer 116:799-807.
57. Wei YJ, Li SL, Li P. 2007. Simultaneous determination of seven active components of Fufang Danshen tablet by high performance liquid chromatography. Biomedical Chromatography 21:1-9.
58. Wu B, Liu M, Zhang S. 2004. Dan Shen agents for acute ischaemic stroke. Cochrane Database System Review CD004295.
59. Xia WJ, Yang M, Fok TF, Li K, Chan WY, Ng PC, Ng HK, Chik KW, Wang CC, Gu GJ, et al. 2005. Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage. Pediatric Research 58:784-790.
60. Yang L, Zou X, Liang Q, Chen H, Feng J, Yan L, Wang Z, Zhou D, Li S, Yao S, Zheng Z. 2007. Sodium tanshinone IIA sulfonate depresses angiotensin II-induced cardiomyocyte hypertrophy through MEK/ERK pathway. Experimental Molecular Medicine 39:65-73.
61. Yang LJ, Jeng CJ, Kung HN, Chang CC, Wang AG, Chau GY, Don MJ, Chau YP. 2005. Tanshinone IIA isolated from Salvia miltiorrhiza elicits the cell death of human endothelial cells. Journal of Biomedical Science 12:347-361.
62. Yang M, Liu A, Guan S, Sun J, Xu M, Guo D. 2006. Characterization of tanshinones in the roots of Salvia miltiorrhiza (Dan-shen) by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry 20:1266-1280.
63. Yu XY, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, Chowbay B, Wen JY, Chan E, Cao J, et al. 2007a. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Current Drug Metabolism 8:365-378.
64. Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Liu PQ, Duan W, Chowbay B, Wen JY, Li CG, et al. 2007b. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge. Current Drug Metabolism 8:325-340.
65. Yu XY, Zhou ZW, Lin SG, Chen X, Yu XQ, Liang J, Duan W, Wen JY, Li XT, Zhou SF. 2007c. Role of ATP-binding cassette drug transporters in the intestinal absorption of tanshinone IIB, one of the major active diterpenoids from the root of Salvia miltiorrhiza. Xenobiotica 37:375-415.
66. Zhang HS, Wang SQ. 2007. Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. Biochemistry and Pharmacology 73:1358-1366.
67. Zhang J, Huang M, Guan S, Bi HC, Pan Y, Duan W, Chan SY, Chen X, Hong YH, Bian JS, et al. 2006. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. Journal of Pharmacology and Experimental Therapy 317:1285-1294.
68. Zhao BL, Jiang W, Zhao Y, Hou JW, Xin WJ. 1996. Scavenging effects of salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochemistry and Molecular Biology International 38:1171-1182.
69. Zhou L, Zuo Z, Chow MS. 2005. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of Clinical Pharmacology 45:1345-1359.
70. Zhou S, Paxton JW, Tingle MD, Kestell P. 2000. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metabolism and Disposition 28:1449-1456.
71. Zhu Y-P. 1998. Chinese materia medica: Chemistry, pharmacology and applications. Amsterdam: Harwood.